Omnicell (NASDAQ:OMCL) Upgraded at StockNews.com

StockNews.com upgraded shares of Omnicell (NASDAQ:OMCLFree Report) from a hold rating to a buy rating in a report published on Monday morning.

Separately, Benchmark reissued a buy rating and issued a $38.00 target price on shares of Omnicell in a report on Tuesday, April 30th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of Hold and a consensus target price of $42.20.

Get Our Latest Stock Analysis on Omnicell

Omnicell Price Performance

OMCL stock opened at $25.61 on Monday. Omnicell has a one year low of $25.12 and a one year high of $75.07. The company’s fifty day moving average price is $29.28 and its 200-day moving average price is $29.87. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.13 and a current ratio of 2.38. The company has a market capitalization of $1.18 billion, a PE ratio of -55.83, a price-to-earnings-growth ratio of 93.23 and a beta of 0.80.

Omnicell (NASDAQ:OMCLGet Free Report) last released its earnings results on Thursday, May 2nd. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.17. Omnicell had a negative net margin of 1.91% and a positive return on equity of 2.41%. The firm had revenue of $246.15 million for the quarter, compared to the consensus estimate of $235.70 million. On average, equities analysts anticipate that Omnicell will post 0.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Panagora Asset Management Inc. bought a new position in Omnicell during the fourth quarter valued at $1,319,000. Vanguard Group Inc. increased its position in Omnicell by 15.1% during the third quarter. Vanguard Group Inc. now owns 5,137,084 shares of the company’s stock valued at $231,374,000 after acquiring an additional 674,824 shares during the last quarter. Pacer Advisors Inc. increased its position in Omnicell by 321,488.8% during the fourth quarter. Pacer Advisors Inc. now owns 1,058,027 shares of the company’s stock valued at $39,814,000 after acquiring an additional 1,057,698 shares during the last quarter. Cadian Capital Management LP bought a new position in Omnicell during the fourth quarter valued at $2,446,000. Finally, Public Sector Pension Investment Board bought a new position in Omnicell during the third quarter valued at $2,517,000. Institutional investors own 97.70% of the company’s stock.

About Omnicell

(Get Free Report)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Recommended Stories

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.